Johnson & Johnson (JNJ) is having a busy week on the regulatory front. The U.S. Food and Drug Administration granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma, marking another win for the pharmaceutical giant's expanding oncology portfolio.

What the Breakthrough Designation Covers

The FDA designation applies to patients whose cancer is recurrent or metastatic and human papillomavirus (HPV)-unrelated, specifically those who have experienced disease progression on or after treatment with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. That's a meaningful patient population that has exhausted several treatment options and needs alternatives.

Johnson & Johnson announced Tuesday that Rybrevant Faspro is already approved in multiple settings for locally advanced or metastatic non-small cell lung cancer. The company is also evaluating the drug in additional solid tumors, including colorectal cancer, suggesting a broader strategic play beyond just head and neck cancer.

The Breakthrough Therapy Designation stems from data presented at the 2025 European Society for Medical Oncology Congress from the open-label Phase 1b/2 OrigAMI-4 study. The results demonstrated promising clinical activity with rapid and durable responses in a heavily pretreated patient population, showing a 45% overall response rate with a median duration of 7.2 months.

What Comes Next in Clinical Development

The subcutaneous formulation of amivantamab is being further evaluated in the ongoing Phase 3 OrigAMI-5 study. This trial is assessing subcutaneous amivantamab in combination with Merck & Co. Inc.'s (MRK) Keytruda (pembrolizumab) and carboplatin versus 5-fluorouracil (5FU) plus pembrolizumab and platinum-based chemotherapy (cisplatin or carboplatin) for HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma, regardless of PD-L1 expression.

Adding to the momentum, the FDA approved on Tuesday a new, simplified monthly dosing schedule for Rybrevant Faspro in combination with oral Lazcluze (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Simplifying dosing schedules matters because it can improve patient compliance and reduce the burden on healthcare systems.

Trellus Health Extends Partnership with Johnson & Johnson

In related news, U.K.-based Trellus Health plc secured a six-month contract extension with Johnson & Johnson's (JNJ) Health Care Systems unit to continue providing Trellus Elevate, which supports patients with moderate to severely active inflammatory bowel disease who are prescribed a Johnson & Johnson therapy for IBD treatment.

The extension came after Trellus achieved specific engagement and satisfaction metrics during the initial pilot phase. Based on these positive metrics, Johnson & Johnson broadened the patient access channels beyond the initial pilot funnel in mid-January 2026, showing continued confidence in the program's performance.

The collaboration, initially signed in January 2025, has been extended to mid-2026 with the same economic terms, including a fixed monthly management fee. That's the kind of contract stability that investors in early-stage healthcare companies appreciate.

Trellus Expands Clinical Trial Platform

Trellus Health is also advancing its TrialSet vertical, which is being deployed into agreed-upon sites with ICON plc (ICLR) for an ongoing, mid-stage immunology and inflammation clinical trial sponsored by Takeda Pharmaceutical Co Ltd (TAK).

The company is also implementing TrialSet with PSI Inc. across two late-stage immunology and inflammation clinical trials sponsored by Sanofi SA (SNY). These implementations will be deployed into agreed-upon sites beginning in mid-second quarter, expanding Trellus's footprint in the clinical trial support space.

"We are establishing a scalable go-to-market model for pharma, with continued focus on disciplined execution, recurring revenue growth, and expansion across immunology and inflammation. We look forward to updating the market on further developments," commented Marla Dubinsky, CEO and Co-founder of Trellus Health.

Financial Outlook for Trellus Health

Trellus Health expects fiscal 2025 revenue to be approximately $545 thousand and has further reduced its monthly cash burn to around $400 thousand by late 2025 from around $440 thousand in October 2025. This was moderately offset by recurring monthly management fees generated during the second half of the year, showing some progress toward financial sustainability.

Stock Performance

Johnson & Johnson shares were trading at $243.31 at the time of publication on Wednesday. The stock is trading near its 52-week high of $246.34, reflecting investor confidence in the company's diversified pharmaceutical pipeline and consistent execution.